Iloprost and tissue-type plasminogen activator differently affect platelet aggregation in platelet-rich plasma and in whole blood
- 1 December 1990
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 60 (5) , 337-342
- https://doi.org/10.1016/0049-3848(90)90216-y
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.Circulation, 1990
- Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin.Circulation Research, 1989
- N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor.Circulation Research, 1989
- Generation of nitric oxide by human neutrophilsBiochemical and Biophysical Research Communications, 1989
- Tissue-type plasminogen activator inhibits aggregation of plateletsLife Sciences, 1988
- Critical Evaluation of Platelet Aggregation in Whole Human BloodAmerican Journal of Clinical Pathology, 1986
- Plasmin inhibition of platelet function and of arachidonic acid metabolism.Journal of Clinical Investigation, 1985
- Dipyridamole Inhibits Platelet Aggregation in Whole BloodThrombosis and Haemostasis, 1983
- Uptake and metabolism of adenosine by human erythrocyte ghostsAmerican Journal of Physiology-Legacy Content, 1972